News ArchivesRead News
Blood lipid marker may help predict risk for Parkinson's disease
Thursday September 19, 2013
News Medical - A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in about 4 to 7 percent of all patients with the disease) also alters how specific lipids, ceramides and glucosylceramides are metabolized. Mayo Clinic researchers have found that Parkinson's patients who do not carry the genetic mutation also have higher levels of these lipids in the blood. Further, those who had Parkinson's and high blood levels were also more likely to have cognitive impairment and dementia. The research was recently published online in the journal PLOS ONE.
The discovery could be an important warning for those with Parkinson's disease. Parkinson's is the second most common neurodegenerative disease after Alzheimer's disease. There is no biomarker to tell who is going to develop the disease -- and who is going to develop cognitive impairment after developing Parkinson's, says Michelle Mielke, Ph.D., a Mayo Clinic researcher and first author of the study.
Cognitive impairment is a frequent symptom in Parkinson's disease and can be even more debilitating for patients and their caregivers than the characteristic motor symptoms. The early identification of Parkinson's patients at greatest risk of developing dementia is important for preventing or delaying the onset and progression of cognitive symptoms. Changing these blood lipids could be a way to stop the progression of the disease, says Dr. Mielke.
There is a suggestion this blood lipid marker also could help to predict who will develop Parkinson's disease and this research is ongoing.
"There is currently no cure for Parkinson's, but the earlier we catch it -- the better chance we have to fight it," says Dr. Mielke. "It's particularly important we find a biomarker and identify it in the preclinical phase of the disease, before the onset even begins."
Dr. Mielke's lab is researching blood-based biomarkers for Parkinson's disease because blood tests are less invasive and cheaper than a brain scan or spinal tap -- other tools used to research the disease.
This work was supported by grants from the National Institute on Aging (U01 AG37526) and from George P. Mitchell and the late Cynthia W. Mitchell. The DEMPARK study was being funded by an unrestricted grant from Novartis and a grant from the International Parkinson Fonds (Deutschland) gGmbH (IPD). The continuation of the study (LANDSCAPE) is part of the Competence Network Degenerative Dementias (KNDD), which is funded by the German Federal Ministry of Education and Research (project number 01GI1008C)). Source: Mayo Clinic.
(19 Sep 2013). News Medical. Blood lipid marker may help predict risk for Parkinson's disease. www.news-medical.net
Recent NewsMay 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression
Apr 21 - TOLEDO Trial: Apomorphine Infusions Reduce 'Off' Time in Parkinson's Disease
Apr 21 - New drug provides long-awaited breakthrough for Parkinson's psychosis
Apr 12 - Obstructive Sleep Apnea Affects Cognition in Parkinson's Disease
Apr 11 - Seattle boxing gym giving hope to Parkinson's patients
Apr 10 - A new rhythm
Apr 10 - Brain cells reprogrammed to make dopamine, with goal of Parkinson's therapy
Apr 6 - FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions
Apr 5 - Combatting the isolation of young onset Parkinson's disease
Apr 1 - The Kid is Alright